Due to the complexity of the roles that galectins play in different stages of cancer progression, galectin-targeted treatments should be sufficiently specific to avoid neutralising the positive effects of those galectins, such as galectin-4, that have the ability to reduce cancer metastasis and progression. This evidence concerns the gene LGALS4 and cancer.